Shares in Syncona, a London-listed life sciences investment group, rose following positive late-stage trial results from its portfolio company Beacon Therapeutics for a potential first treatment for X-linked retinitis pigmentosa (XLRP), a severe inherited retinal disease that causes vision loss.

The pivotal Vista study demonstrated that Beacon’s gene therapy candidate, laruzova, met its primary endpoint by showing a statistically significant improvement in a measure of vision among male patients with XLRP caused by mutations in the RPGR gene—the most common cause of the condition. According to Beacon, a significant proportion of treated patients were able to read smaller letters on an eye chart compared to their baseline vision. Full clinical data from the trial are scheduled for presentation at the American Academy of Ophthalmology annual meeting in October.

XLRP currently has no approved treatments and affects more than 20,000 patients across the United States and Europe. Beacon’s promising trial results position laruzova as a potential first therapy for this blinding disease. The company plans to initiate discussions with regulatory authorities to seek authorization for the gene therapy.

Beacon Therapeutics was formed three years ago following Syncona's acquisition and fundraising efforts, which included acquiring late-stage assets from the US public company AGTC. Syncona retains a 38.4 percent stake in Beacon, with its shareholding valued at approximately £183.4 million as of June. The positive trial results were described by Syncona as a "key value inflection point," and the London-listed company’s shares closed up 5.2 percent, valuing Syncona at about £724 million.

Chris Hollowood, Syncona’s chief executive, said the trial outcome marked a "significant milestone for patients impacted by a devastating blinding condition." He highlighted Syncona’s role in supporting Beacon through clinical development, regulatory navigation, and funding during the late stages of the therapy’s progress.

Jason Menzo, chief executive of the Foundation Fighting Blindness, expressed optimism about the development, stating that for those living with XLRP, the results were “the news we have been waiting years to hear.”

Beacon has raised a total of approximately $367 million to date to advance its gene therapy programs, with laruzova representing a critical step toward addressing an unmet medical need in inherited retinal diseases.